Physician profile
Roger Hill
NPI 1043215023
$9,720.67
in general payments reported to CMS, 2019-2025
31 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $880 · 2021: $970 · 2022: $1,438 · 2023: $2,179 · 2024: $1,468 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,153.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,870.65 | 2019-2025 | Eluvia, General - Vascular Intervention, Ekosonic |
| Abiomed | $1,488.25 | 2022-2025 | Impella |
| Abbott Laboratories | $1,194.23 | 2019-2025 | Aveir, Jot Dx, Ultreon |
| Medtronic, INC. | $696.26 | 2021-2025 | Cobalt Dr Mri Surescan, Selectsecure, Affera Mapping System |
| Amgen INC. | $546.81 | 2019-2023 | Repatha |
| Shockwave Medical, INC | $543.79 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave S4 |
| Novartis Pharmaceuticals Corporation | $444.96 | 2019-2025 | |
| Pfizer INC. | $390.27 | 2019-2024 | |
| Medtronic Vascular, INC. | $322.62 | 2019-2020 | |
| Cvrx, INC. | $315.83 | 2023-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $297.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $180.32 | 2019-2024 | Farxiga |
| Avinger INC. | $179.61 | 2019-2023 | Pantheris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.08 | 2019-2024 | Lifevest |
| Livanova USA, INC. | $152.40 | 2023 | Lifesparc |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $137.08 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Sanofi-Aventis U.S. LLC | $116.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.93 | 2019-2021 | |
| Irhythm Technologies, INC. | $104.12 | 2019-2021 | |
| Daxor Corporation | $92.59 | 2024 | Bva-100 |
| Cordis US Corp. | $51.58 | 2024-2025 | Mynx Control Venous, Mynx Control |
| Edwards Lifesciences Corporation | $49.43 | 2024-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $48.98 | 2020-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $48.92 | 2021-2023 | Verquvo |
| Bard Peripheral Vascular, INC. | $40.23 | 2021-2025 | Rotarexs 6 F X 135 Cm |
| Haemonetics Corporation | $39.30 | 2023 | Teg6s Hemostasis System |
| Inspire Medical Systems, INC. | $23.54 | 2025 | Inspire |
| Biotronik INC. | $20.08 | 2022 | |
| Philips North America LLC | $17.65 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2024 | |
| Esperion Therapeutics, INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.